Halozyme Therapeutics Inc

HALO

Equity

ISIN US40637H1095 / Valor 1814799

NASDAQ (2024-10-25)

USD 49.25-0.10%

Halozyme Therapeutics Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Halozyme Therapeutics Inc is a biopharmaceutical company that specializes in developing and commercializing novel drug delivery technologies. With over three decades of experience, the company has broadened its technological offerings to include a variety of auto-injectors for subcutaneous and intramuscular administration, catering to specific patient and therapeutic requirements. At the core of Halozyme's innovation is its ENHANZE® drug delivery technology, which leverages the proprietary enzyme rHuPH20 to enhance the subcutaneous delivery of injectable drugs and fluids. This technology has been commercially validated and is notable for its potential to significantly improve patient experience by transforming lengthy IV infusions into quick subcutaneous injections. Through its focus on creating custom-designed drug delivery devices and its ENHANZE® platform, Halozyme aims to address and reduce the treatment burden for patients across various therapeutic areas.

Summarized from source with an LLMView SourceSector: Technology

Total Revenue

Halozyme Therapeutics Inc. reported total revenue of $231 million for the second quarter of 2024, marking a 5% increase compared to the same period in the previous year. This growth was driven by strong performance across its product portfolio and increased royalty revenues.

Adjusted EBITDA

The company achieved an Adjusted EBITDA of $137 million in Q2 2024, representing a 19% increase year-over-year. This improvement reflects Halozyme Therapeutics Inc.'s efficient cost management and robust revenue growth.

Non-GAAP Diluted EPS

Halozyme Therapeutics Inc. reported a non-GAAP diluted earnings per share (EPS) of $0.91 for the second quarter of 2024, which is a 23% increase from the same quarter in the previous year. This rise in EPS underscores the company's strong financial performance and profitability.

Royalty Revenue

Royalty revenue for Halozyme Therapeutics Inc. in Q2 2024 was $125 million, up 12% from the previous year. The increase in royalty revenue was primarily due to higher sales of products utilizing the company's ENHANZE® technology.

Share Repurchase

During the second quarter of 2024, Halozyme Therapeutics Inc. completed a $250 million accelerated share repurchase (ASR) program. This move is part of the company's ongoing efforts to return value to shareholders and reflects confidence in its long-term growth prospects.

Summarized from source with an LLMView Source

Key figures

47.8%1Y

28.1%3Y

226%5Y

Performance

35.9%1Y

38.0%3Y

40.1%5Y

Volatility